Is Eli Lilly using ‘granfluencers’ to raise awareness of its Alzheimer’s med?
By
Marc Iskowitz
Sep 04, 2024
Here’s why older internet celebs — granfluencers — soon might be making rounds on the Alzheimer’s drug marketing scene.
What happens if biomarker tests spot Alzheimer’s before people show symptoms?
By
Kristen Fischer
Aug 05, 2024
As of now, no therapy is approved by the Food and Drug Administration for people at risk of Alzheimer’s disease who don’t have symptoms. But blood tests that can spot biomarkers linked to the disease...
New practices, strategies help improve life for those with dementia, caregivers: report
By
Kimberly Bonvissuto
Jul 26, 2024
New practices and strategies are helping senior living communities improve the everyday lives of residents living with dementia and their caregivers, according to a new report from Sodexo that aims to...
FDA delays decision on new Alzheimer’s drug
Mar 08, 2024
Instead of approving the new Alzheimer’s drug donanemab this month, as was expected, the U.S. Food and Drug Administration will now require the experimental medication be scrutinized more closely...
16 assisted living operators to help Alzheimer’s Association test dementia care program
By
Lois A. Bowers
Sep 20, 2018
Sixteen assisted living operators across 12 states and the nation’s capital have signed on to help test an Alzheimer’s Association program that could enhance the care of residents with dementia.
Memory care will be big growth area in 2018, senior living leaders predict
By
Lois A. Bowers
Feb 14, 2018
Memory care will be the biggest growth area in senior living and long-term care in 2018, predict executives participating in Lancaster Pollard’s “2018 Seniors Housing and Care Survey,”...
Aegis Living, SLR recognized for achieving elevated memory care standards
By
Kimberly Bonvissuto
Feb 26, 2024
Two assisted living and memory care providers have earned certifications for meeting elevated standards of care for people living with dementia.
FDA approves new drug to treat Alzheimer’s
Jul 02, 2024
In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including...
Passive data collection could soon lead to a treasure chest of new data on neurological disorders
By
Aaron Dorman
Oct 06, 2023
Wearable technologies, like smart watches and headbands, have engendered a new wave of studies on neurological disorders.
Alzheimer’s cure would result in assisted living losses of $16 billion in annual revenues, 110,000...
By
Lois A. Bowers
Sep 17, 2019
A “novel, simple and fast-acting” cure for Alzheimer’s disease would be a “medical miracle” but would result in a loss of $16.3 billion in annual revenues for the assisted living industry, according...